Company BIOTON S.A.

Equities

BIO

PLBIOTN00029

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Market Closed - Warsaw S.E. Other stock markets 11:55:40 2024-04-29 am EDT			5-day change	1st Jan Change
3.505 ^PLN	0.00%		-0.43%	-1.82%

Mar. 28	BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

Number of employees: 357

PLN in Million	2022	Weight	2023	Weight	Delta
Bioton PL 94.5 %	228	98.0 %	172	94.5 %	-24.86%
Biolek 5.5 %	5	2.0 %	10	5.5 %	+112.24%

PLN in Million	2022	Weight	2023	Weight	Delta
Poland 55.7 %	100	42.8 %	101	55.7 %	+1.40%
Global 21.5 %	54	23.4 %	39	21.5 %	-28.46%
Libya 11.8 %	-	-	21	11.8 %	-
Vietnam 6.0 %	17	7.4 %	11	6.0 %	-36.21%
Bangladesh 2.4 %	-	-	4	2.4 %	-
Ukraine 1.8 %	-	-	3	1.8 %	-
China 0.9 %	47	20.2 %	2	0.9 %	-96.51%

Managers	Title	Age	Since
Jeremy Launders CEO	Chief Executive Officer	-	20-10-29
Anna Grabowska DFI	Director of Finance/CFO	-	18-08-31
Jolanta Lis ADM	Chief Administrative Officer	-	16-12-31
Dariusz Gurtowski CTO	Chief Tech/Sci/R&D Officer	-	-
Michal Deptuch COO	Chief Operating Officer	-	98-12-31
Katarzyna Stalinska IRC	Investor Relations Contact	-	18-10-31
Ewelina Romanska HRO	Human Resources Officer	-	21-12-31
Malgorzata Masierek SAM	Sales & Marketing	-	07-12-31
Kamila Musnicka LAW	General Counsel	44	16-12-31
Adam Tomasz Polonek PRN	Corporate Officer/Principal	47	05-12-31

Members of the board	Title	Age	Since
Tomasz Siembida BRD	Director/Board Member	-	21-12-31
Ju Bo Liu BRD	Director/Board Member	51	21-12-31
Nicola Cadei BRD	Director/Board Member	-	19-12-02
Dariusz Roman Trzeciak BRD	Director/Board Member	56	19-06-27
Vaidyanathan Viswanath BRD	Director/Board Member	62	21-12-31
Ramesh Rajentheran BRD	Director/Board Member	-	19-06-27
Valery Yeo BRD	Director/Board Member	-	22-06-29
Jia Li CHM	Chairman	-	22-06-29

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	85,864,200	34,611,008 ( 40.31 %)	0	40.31 %

Name	Equities	%	Valuation
YIFAN PHARMACEUTICAL CO., LTD. 31.72 %	27,235,211	31.72 %	24 M zł
CEE Equity Partners Ltd. 13.16 %	11,303,704	13.16 %	10 M zł
Troqueera Enterprises Ltd. 9.877 %	8,480,570	9.877 %	8 M zł
Wen Jun Cui 5.000 %	4,293,210	5.000 %	4 M zł
Altus TFI SA (Investment Management) 0.4659 %	400,000	0.4659 %	358 096 zł
PKO BP Bankowy PTE SA 0.2853 %	245,000	0.2853 %	219 334 zł
Pekao TFI SA 0.0574 %	49,322	0.0574 %	44 155 zł
BNP PARIBAS ASSET MANAGEMENT Netherlands NV 0.0326 %	28,013	0.0326 %	25 078 zł
Dimensional Fund Advisors Ltd. 0.0317 %	27,244	0.0317 %	24 390 zł
Pekao Investment Management SA 0.0304 %	26,093	0.0304 %	23 359 zł

BIOTON SA

ul. Poznanska 12 Ozarow Mazowiecki

05-850, Warsaw

+48 22 721 4000

http://www.bioton.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTON S.A.	-1.82%	74.34M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs